LB03A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT OR PLACEBO ON STANDARD OF CARE IN PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS

David Jayne; Mary Dooley; David Wofsy; Tsutomo Takeuchi; Ana Malvar; Andrea Doria; Juanita Romero-Díaz; Tak Chan; Ayanbola Elegbe; Gerald Appel; Richard Furie; Michael Maldonado

doi:10.1093/ndt/gfy146.lb03

LB03A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT OR PLACEBO ON STANDARD OF CARE IN PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy146.lb03 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i636-i637

Author(s):

David Jayne ◽

Mary Dooley ◽

David Wofsy ◽

Tsutomo Takeuchi ◽

Ana Malvar ◽

...

Keyword(s):

Lupus Nephritis ◽

Standard Of Care ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Class Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Active Class

Download Full-text

OP0253 A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritis

10.1136/annrheumdis-2018-eular.3451 ◽

2018 ◽

Author(s):

R. Furie ◽

M.A. Dooley ◽

D. Wofsy ◽

T. Takeuchi ◽

A. Malvar ◽

...

Keyword(s):

Lupus Nephritis ◽

Standard Of Care ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Class Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Active Class

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

Arthritis & Rheumatology ◽

10.1002/art.39722 ◽

2016 ◽

Vol 68 (9) ◽

pp. 2174-2183 ◽

Cited By ~ 55

Author(s):

Brad H. Rovin ◽

Ronald F. van Vollenhoven ◽

Cynthia Aranow ◽

Carrie Wagner ◽

Robert Gordon ◽

...

Keyword(s):

Lupus Nephritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text

Abstract CT221: CHRONOS-3: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of phosphatidylinositol-3 kinase (PI3K) alpha/delta inhibitor copanlisib in combination with rituximab in patients with relapsed indolent B-c

10.1158/1538-7445.am2015-ct221 ◽

2015 ◽

Author(s):

Pier Luigi Zinzani ◽

John F. Gerecitano ◽

Marius Giurescu ◽

Rodrigo Ito ◽

Katharina Mueller ◽

...

Keyword(s):

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Phosphatidylinositol 3 Kinase ◽

Double Blind ◽

Double Blind Placebo ◽

Phosphatidylinositol 3

Download Full-text

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)

Cardiovascular Drugs and Therapy ◽

10.1007/s10557-011-6304-x ◽

2011 ◽

Vol 25 (S1) ◽

pp. 33-45 ◽

Cited By ~ 91

Author(s):

Masunori Matsuzaki ◽

◽

Masatsugu Hori ◽

Tohru Izumi ◽

Masatake Fukunami

Keyword(s):

Heart Failure ◽

Standard Treatment ◽

Volume Overload ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Heart Failure Patients

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768310.793547377 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01860-7 ◽

2021 ◽

Vol 21 ◽

pp. S376-S377

Author(s):

Umberto Vitolo ◽

Grzegorz S. Nowakowski ◽

John M. Burke ◽

Christopher P. Fox ◽

Marek Trneny ◽

...

Keyword(s):

Cell Lymphoma ◽

B Cell Lymphoma ◽

Phase Iii ◽

Controlled Study ◽

Newly Diagnosed ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH)

10.1183/13993003.congress-2019.pa4750 ◽

2019 ◽

Author(s):

David Badesch ◽

Simon Gibbs ◽

Mardi Gomberg-Maitland ◽

Marc Humbert ◽

Vallerie Mclaughlin ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Standard Of Care ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Pulmonary Arterial

Download Full-text

No. 128 Efficacy and Safety of AbobotulinumtoxinA in the Treatment of Cervical Dystonia: A Phase III Randomized Double-Blind Placebo-Controlled Study

PM&R ◽

10.1016/j.pmrj.2014.08.256 ◽

2014 ◽

Vol 6 (8) ◽

pp. S122

Author(s):

Philippe Picaut ◽

Werner Poewe ◽

Katalin Bihari ◽

Marta Banach

Keyword(s):

Cervical Dystonia ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.15733 ◽

2020 ◽

Author(s):

Seong Jun Seo ◽

Bong Seok Shin ◽

Joo‐Heung Lee ◽

Haeyoun Jeong

Keyword(s):

Plaque Psoriasis ◽

Korean Population ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text